Rhenman & Partners Asset Management Ab Viking Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $959 Million
- Q4 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 90,000 shares of VKTX stock, worth $2.51 Million. This represents 0.38% of its overall portfolio holdings.
Number of Shares
90,000
Previous 102,500
12.2%
Holding current value
$2.51 Million
Previous $6.49 Million
44.2%
% of portfolio
0.38%
Previous 0.54%
Shares
10 transactions
Others Institutions Holding VKTX
# of Institutions
467Shares Held
65.8MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$284 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$168 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$138 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$72.5 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$60.3 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.14B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...